GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: GNVC
- Previous Close: $6.61
- 50 Day Moving Average: $6.28
- 200 Day Moving Average: $2.37
- 52-Week Range: $2.70 - $14.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.35
- P/E Growth: 0.00
- Market Cap: $14.96M
- Outstanding Shares: 2,273,000
- Beta: 3.14
- Net Margins: -909.71%
- Return on Equity: -88.05%
- Return on Assets: -64.04%
Companies Related to GenVec:
- Current Ratio: 6.00%
- Quick Ratio: 6.00%
What is GenVec's stock symbol?
GenVec trades on the NASDAQ under the ticker symbol "GNVC."
When did GenVec's stock split? How did GenVec's stock split work?
GenVec's stock reverse split on Thursday, December 1st 2016. The 1-10 reverse split was announced on Wednesday, November 16th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2016. An investor that had 100 shares of GenVec stock prior to the reverse split would have 10 shares after the split.
Where is GenVec's stock going? Where will GenVec's stock price be in 2017?
3 brokers have issued twelve-month price objectives for GenVec's shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate GenVec's stock price to reach $11.33 in the next twelve months.
When will GenVec announce their earnings?
GenVec is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
Who owns GenVec stock?
GenVec's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (2.47%). Company insiders that own GenVec stock include Douglas E Brough, Douglas J Swirsky and Stefan Loren.
Who bought GenVec stock? Who is buying GenVec stock?
GenVec's stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. Company insiders that have bought GenVec stock in the last two years include Douglas E Brough, Douglas J Swirsky and Stefan Loren.
How do I buy GenVec stock?
Shares of GenVec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of GenVec stock cost?
One share of GenVec stock can currently be purchased for approximately $6.58.